AX68c / Xomics Biopharma - LARVOL DELTA

Novel xCT-targeted biologics significantly suppress metastasis, improve survival, and sensitize primary tumors to chemotherapy in TNBC xenograft models (AACR 2024) - "In orthotopic MDA-MB-231 xenografts, AX68c treatment significantly reduced tumor metastasis and sensitized primary tumors to cisplatin and paclitaxel. We conclude that our anti-xCT biologics may provide novel targeted therapies for M/MSL-subtype TNBC and metastatic tumors with a large mesenchymal component.1. Viswanathan, et al., Nature, 2017; 2. Wang, et al., npj Precision Oncology, 2021; 3."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • SLC7A11 • TGFB1 • TNFA